ARTICLE | Company News
OxiGene, BMY terminate cancer deal
October 24, 2001 7:00 AM UTC
OxiGene (OXGN; SSE:OXGN) and Bristol-Myers (BMY) terminated a 1999 deal under which BMY received worldwide development rights to OXGN's Combretastatin compounds, including Combretastatin A4 Prodrug ( CA4P), a phosphatase activated tumor vascular targeting agent in Phase I clinical trials. According to OXGN, the compound was no longer consistent with BMY's strategic profile for development. OXGN will continue Combretastatin development. ...